Compare BLZE & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | FHTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.6M | 247.1M |
| IPO Year | 2021 | 2020 |
| Metric | BLZE | FHTX |
|---|---|---|
| Price | $4.85 | $5.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $9.50 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 872.7K | 168.3K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $141,859,000.00 | $24,518,000.00 |
| Revenue This Year | $16.43 | $47.50 |
| Revenue Next Year | $11.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.73 | N/A |
| 52 Week Low | $3.94 | $2.95 |
| 52 Week High | $10.86 | $6.79 |
| Indicator | BLZE | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 74.06 |
| Support Level | $4.44 | $4.21 |
| Resistance Level | $5.09 | $4.59 |
| Average True Range (ATR) | 0.21 | 0.32 |
| MACD | 0.15 | 0.12 |
| Stochastic Oscillator | 61.19 | 90.52 |
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.